Zinc and aliphatic halogen-carboxylic acid salts for treatment of skin neoplasm and visible mucosa tissues |
|
IPC classes for russian patent Zinc and aliphatic halogen-carboxylic acid salts for treatment of skin neoplasm and visible mucosa tissues (RU 2261243):
          
 The method of producing antiglomerular / 2190592
The invention relates to a method of producing antiglomerular based on calcium stearate, which finds application in the petrochemical industry for preparation of synthetic rubbers
 Composition based on polyvinyl chloride for the manufacture of films / 2083610
The invention relates to compositions based on polyvinyl chloride to obtain the films used for the manufacture of containers for food products and medicines
 The method of obtaining propionic acid / 2134682
The invention relates to a method for production of propionic acid by hydroxycarbonylmethyl ethylene carbon monoxide in the environment of water and organic Karabanovo acid2-C4
 Method for preparing ferrous (ii) acetate / 2259994
Invention relates to a method for preparing acetic acid salts, in particular, anhydrous ferrous (II) acetate. Method for preparing anhydrous ferrous (II) acetate involves interaction of metallic iron with acetic acid in the presence of oxidizing agents of ferric oxide Fe2O3 or Fe3O4 and molecular iodine in the mole ratio acetic acid : acetic anhydride : iron oxide = 100:(6-20):(2-2.5), respectively, and in the mole ratio iron oxide : iodine = 100:6.3. The process is carried out at temperature 80°C in the beaded mill of vertical type with high-rotation blade mixer and reflux condenser in the mass ratio of glass beads and liquid phase in the charge = 1:1. The process is carried out with periodic taking off samples of the end product solid phase by filtering and the following recover filtrate and feeding with acetic acid and iron oxide. For compensation of components loss of liquid phase in filtering there are recovered into reactor to the repeated process that is carried out for four times at a time. All procedures of the basic process and filtration are carried out in nitrogen medium. Preferably, method involves using hematite, γ-oxide, iron minium, magnetite or Fe3O4 x 4 H2O as the iron oxide source. Invention provides possibility for preparing anhydrous ferrous (II) acetate and simplifying method due to excluding the evaporation stage in isolation of salt.
Method for preparing copper (ii) acetate monohydrate / 2246480
Invention relates to a method for preparing copper (II) acetate monohydrate that represents organic carboxylic acid salt. Copper (II) acetate monohydrate is prepared by crystallization from solution obtained by mixing acetic acid, alkaline metal acetates or ammonium with copper-containing spent solution used in etching printing boards. Method provides reducing cost of the proposed method for preparing copper (II) acetate monohydrate, retaining purity of product with simultaneous utilization of toxic waste in electronic engineering manufacture - the spent solution in etching printing boards. Also, invention provides reducing material consumptions in preparing copper (II) acetate monohydrate, expanding assortment of materials used for its preparing and utilization of toxic waste in electronic engineering manufacture. Product obtained by the proposed method can be used as pigment, fungicide and copper microfertilizer in agriculture, as catalyst in processes of polymerization, as a stabilizing agent of artificial fibers, for preparing galvanic solutions and preparing other copper compounds.
 The way to get calcium acetate / 2156757
The invention relates to the production of salts of acetic acid
The method of obtaining crystalline sodium acetate from waste products chemical products / 2024486
The invention relates to waste disposal and the simultaneous achievement of commercial products and can be used in other industries where liquid wastes with a content of acetic acid
Monochloroacetic acid production process / 2253650
Two-stage process of production of monochloroacetic acid comprises acetyl chloride preparation stage and second stage wherein acetyl chloride is converted into desired product. Acetyl chloride is obtained via chlorination of acetic anhydride in continuous mode. Second stage is also carried out continuously in two steps involving recycling of acetyl chloride and acetic acid. Acetyl chloride is first chlorinated in UV activated chlorine flow in hydrodynamic mixing chamber to form nonochloroacetyl chloride. In the second step, nonochloroacetyl chloride recovered from reaction mixture is vaporized and fed into hydrodynamic mixing chamber to be mixed with 99.9% acetic acid. Resulting reaction mixture, containing monochloroacetic acid and acetyl chloride, is passed to heat exchanger at 80°C, wherein acetyl chloride is separated in thin layer from condensed monochloroacetic acid and returned to the first step.
 A method of obtaining a perfluorinated ethers with terminal functional groups / 2179548
The invention relates to a method for perfluorinated ethers with terminal functional groups of the formula: RfO[CF(CF3)-CF2O]n-CF(CF3)-MOR, where Rf= perfluoroalkyl C1-C8, n= 0-3, X= F or IT, which are used as intermediate products for the synthesis of perfluoroalkyl vinyl ethers, for obtaining surfactants, chemically and thermally stable liquids, polymers
 Method for preparing anti-inflammatory, wound-healing, capillary-strengthening and immunomodulating agent / 2259835
Invention relates to a method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent. Method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent is carried out for four stages. At the first stage violet tricolor and/or field milled herb is extracted with fluidized carbon dioxide under the definite condition followed by separation of grist from lipophilic fraction of extract; at the second stage defatted grist is subjected for three-fold extraction by remaceration method under the definite condition followed by treatment and purification of combined extract, treatment, condensation and preparing liquid alcoholic extract; at the third stage liquid alcoholic extract is used for preparing polysaccharide and flavonoid complexes by precipitation of polysaccharide with three-fold volume of 96% ethyl alcohol and the following drying at the definite temperature; at the forth stage grist after isolation of polysaccharide and flavonoid complexes is used for preparing pectins by treatment with three-fold volume of ammonium oxalate solution at the definite temperature, evaporation and drying. Liquid alcoholic is evaporated to 1/5 of the parent volume, dried by spraying drying or lyophilic drying at definite temperatures. Each end product prepared at each stage can be used as both independent medicinal formulation and can be used for preparing other medicinal formulations (tablets, capsules, suppositories, films). Also, invention relates to a method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent that involves extraction of violet tricolor and/or field milled herb with 70% ethyl alcohol by infusion for a definite time followed by purification of the end product, settling at the definite temperature and filtration. Method provides preparing agent with broad pharmacological pattern of action and provides the maximal using the medicinal vegetable raw.
Wound-healing remedy / 2259816
The suggested wound-healing remedy includes a gel-forming agent, an active substance and distilled (deionized) water. As the active substance it contains Mexidol (2-ethyl 6-methyl 3-oxypyrridine succinate) at the following ratio of components, weight%: gel-forming agent 0.5-5.0, stabilizing agent 0.01-0.8, conservant 0.01-1.0, Mexidol 0.01-10.0, distilled (deionized) water - the rest. The suggested remedy is highly efficient. It is of pronounced wound-healing action in 1, 2 and 3 phases of wound process. It quickly liquidates inflammatory processes, decreases painfulness, edema, considerably improves the state of affected tissues, accelerates reparative-degenerative processes and terms of epithelization. It possesses the wide spectrum of action, manifests pronounced action at treating different skin and mucosal lesions - wounds, fissures, bedsores, trophic ulcers of different genesis, surface burns of 1-3 degree, radiation lesions, it, also, removes skin microlesions that possess the nature of cosmetic defects, moreover, it improves skin structure.
 Method for treating lichen ruber planus / 2258516
The present innovation deals with introducing desensitizing remedies, local application of hormonal preparation onto oral mucosa and, also, a keratoplastic preparation as 4%-chitosan water-insoluble colloid solution at deacetylation degree of 0.95, molecular weight of 100-120 kD. This preparation should be applied with a thin layer onto affected parts of oral mucosa for 30 d which should be pre-treated with 1%-hydrogen peroxide solution and dried. Then therapy should be continued with the above-mentioned chitosan solution once daily after meals and once nocturnally, for 30 d, as well. The innovation provides quick interruption of inflammation, complete epithelization due to high adhesion of preparation at oral mucosa.
Medicinal agent eliciting wound-healing effect / 2258515
Invention relates to manufacturing medicinal preparations with wound-healing effect, in particular, to preparation with wound-healing effect comprising an agent stimulating epithelization. The wound-healing agent comprises vitamin E in concentrations 0.01-5.0 wt.-% in chitosan gel. Preferable variant represents applying chitosan gel formed by fractionated low-molecular chitosan of molecular mass from 10 to 20 kDa, or from 20 to 50 kDa, or from 50 to 300 kDa taken in the concentration from 1.0 to 10.0 wt.-%. Except for, it is possible additional applying antibacterial agent in wound-healing agent taken among the following order: chloramfenicol, lyncomycin, metronidazol, ciprofloxacin, benzalkonium chloride, additional using an antibacterial agent and lidocaine in agent, additional using an antibacterial agent and adrenaline in agent, and additional using hydrocortisone in the concentration 0.5 wt.-% in agent. Invention provides preparing wound-healing effect that occurs early essentially in epithelization and without formation of colloidal scars and reduces time for appearance of tissue regeneration markers.
Method for treatment of suppurative wound / 2257211
Method involves every day covering a wound with an agent comprising of pig spleen homogenate and oxygenated with perfluorane taken in the following amounts: 100 g of pig spleen homogenate and 10 ml of oxygenated perfluorane. Invention promotes to accelerating sanitation of suppurative wounds due to activation of topical immunity and activation of regenerating processes. Invention can be used in treatment of suppurative wounds.
Ointment for treatment of burn, suppurative and infected wound of different etiology and method for treatment of burn, suppurative and infected wound / 2256441
Invention relates to curative ointments with anti-inflammatory effect and with biostimulating properties for treatment of burns, suppurative and infected wounds of different etiology and to a method for treatment above said diseases using the ointment said. The proposed ointment comprising bee wax and greasy basis comprises colophony additionally. As greasy basis the ointment comprises butter and vegetable oil in the following ratio of components, wt.-%: bee wax, 20-30; butter, 30-40; vegetable oil, 15-25; colophony, 15-25. Method involves applying ointment by thin layer 0.5-3 mm on dense cotton fabric, its applying to damaged site, keeping and removing ointment with change of bandage 1-3 times per 24 h for 3-14 days. Method provides enhancing the therapeutic effectiveness of ointment due to significant acceleration the healing process of suppurative wounds and insidious furuncles being the ointment doesn't cause irritating effect.
Agent for treatment of suppurative wound / 2254120
Invention relates to medicinal preparations used for treatment of suppurative wounds. Invention involves applying boric acid (powder) and multi-component ointments on water-soluble base (Laevomecolum or Laevosinum) taken in the ratio 1:10 and used for treatment of suppurative wounds. Invention provides the development of agent exhibiting the expressed antibacterial, dehydrating and necrolytic effect.
 Method for therapy and control for the process of treating scars as a result of acne vulgaris / 2252796
One should apply an applicator onto affected parts of skin that contains 5-aminolevulinic acid at concentration of 5-20%. After keeping and removing the applicator it is necessary to irradiate with light at wave length being 630 ± 10 nm and energy density of 10-1200 J/sq. cm. Control should be carried out due to evaluating the concentration of photosensitizer at affected parts of skin due to fixing fluorescence ranges at all basic stages of photodynamic therapy. The method enables to adjust skin relief and achieve scars' whitening and their regression.
Method for manufacturing remedy for prophylaxis of wound suppuration / 2252749
The innovation deals with manufacturing remedies to prevent wound suppuration based upon polymeric matrix and antimicrobial substance due to mixing components in solution, forming the film to obtain a powder-like medicinal form by providing the safety of antimicrobial activity of medicinal preparation. The obtained remedy is completely biodestructed in the body and requires no repeated operation on its removal after the end of tissue regeneration processes.
Ointment for treating burns and other skin diseases / 2252018
The present innovation deals with preparing ointments to be applied at treating both surface and deeply penetrating cutaneous burns and other skin diseases, as well. Composition of the suggested ointment includes, weight%: 45…67% food sunflower oil, 15…37% food olive oil, 1…2% Calendulae officinalis extract, 0.8…1.8% labdanum, 2.5…8% colophony, 6.5…11.5% white bee wax, 0.7…1.8% the main bismuth gallate and 0.7…1.8% camphor. The suggested ointment is highly efficient for rapid and successful treatment of burns III and IV degree. It should be also applied for treating shin's ulcer and, also, in gynecology - for treating inflammation of uterine cervix.
 The use of derivatives of fumaric acid in transplantation medicine / 2210364
The invention relates to the application of certain monoalkyl esters of fumaric acid or in the form of their salts or in the form of the free acid, individually or in combination with dialkylamino, to obtain pharmaceutical compositions for use in transplantation medicine
 The use of fumaric acid derivatives / 2197963
The invention relates to containing certain monoalkyl esters of fumaric acid in the form of salts or the free acid individually or in combination with dialkylamino for the treatment of arthritis or multiple sclerosis, as well as reactions "graft versus host"
|
FIELD: organic chemistry, medicine, dermatology. SUBSTANCE: invention relates to zinc and aliphatic halogen-carboxylic acid salts that can be used in treatment of benign neoplasms of skin and visible mucosa tissues. Invention proposes the following formula of zinc and aliphatic halogen-carboxylic acid salts: (1): EFFECT: enhanced and valuable properties of agents. 13 ex
The invention relates to medicine, namely to dermatology, namely to new salts of zinc and haloalkaliphilic acids of the aliphatic series, which can be used for the treatment of benign lesions of skin and visible mucous membranes of the skin. Known selenium compound with kaloxylos acid or its anhydride (EP 1293498, 30.08.2001). The connection is used for the treatment of benign skin tumors of different nature, including the mucous membranes of the skin. Known also use for the treatment of papillomatosis mucous membranes and upper respiratory tract propionovoi ointment with low toxicity (″Properidine antitumor agent″ VNIIOFI, issue 3, M, 1973, s-138). The percentage of effectiveness of treatment in this case is equal to 70-75%. Prospidin most effective in the treatment of precancerous diseases. Given the pronounced deep tissue damage, prospidin impractical to use for the treatment of benign lesions of skin and mucous coats. The closest technical solution to the claimed nature and the achieved effect is the product for local treatment of superficial lesions of the skin and mucous membranes on the basis of the reaction of interaction between the solution of 1-5,5 M nitric acid with 45-170 the primary mmol C1-C5-alkanol on 1 l of nitric acid(RU 2118160, 23.06.1993). The drug, in particular, is indicated for the local treatment of superficial benign skin changes, such as Verrucae (for example, Verrucae vutgares and Verrucae plantares), seborrheic and actinic keratoses and Condylomata, and superficial benign mucosal changes, such as benign lesions in the cervical area, such as erosion, Ovula Nabothi polyps in the area of the cervical canal, Condylomata. However, when use of the drug recurrence is 30-40%, incomplete healing - 45%. The drug is a danger to personnel and requires precaution. The aim of the invention is the creation of an original low-toxic stable highly effective drug for the treatment of benign tumors of the skin and visible mucous membranes of the skin, with good tolerability, lack of treatment complications, healing without scar formation changes. Proposed chemical formula zinc salts and haloalkaliphilic acids of the aliphatic series having the form
where in the formula the halogen atom may be Fluorine (F), Chlorine (Cl), Bromine (Br) or Iodine (J). Source materials can be of various chemical products containing zinc and solutions aliphatic haloalkaliphilic acids. The final product before the hat is a solution of zinc salts and haloalkaliphilic acids. It is brown in color, with a pH of 2.2-3.0, LD50 1100 mg/kg of the Drug is practically non-toxic, does not penetrate into the body, has no system, teratogenic, embryotoxic and carcinogenic properties. The drug selectively dehydrates the tissue has intravitally locking action on the fabric. After removal of pathological tissue healing and regeneration is completed within two weeks without significant side effects. The concentration of zinc in the product depends on the type of source chemical ingredients and can be between 2.5-25%. Chemical product invariant for many years when stored at room temperature in a closed dark glass jar. The stated substance may be used only for local use. As a medicine it could be in the form of a solution in a concentration of from 5 to 45%. The recommended dose for one defeat from 0.1 to 2.0 cm2in liquid form, from 0.03 to 0.2 ml For numerous defeats, the dose may be from 0.2 to 2.00 ml Achieved technical result consists in the creation of original drug for the treatment of benign tumors of the skin and visible mucous membranes of the skin, low-toxic, fast-acting with a pronounced therapeutic effect, with good tolerability, lack of treatment complications, healing without education the Oia scar tissue. The creation of the drug allows to expand the range of products for the treatment of such diseases. The product is easy to use, safe for patients and health professionals, and requires no particular restrictions on its behavior. From patent and scientific and technical information is not known chemical formula zinc salts and haloalkaliphilic acids of the aliphatic series, which could be used for local treatment of benign tumors of the skin and visible mucous membranes of the skin. The synthesis of the claimed substances based on the use of available and inexpensive raw materials and ease. The claimed substance obtained by reaction of the oxide or hydroxide, or carbonate of zinc with haloalkaline acids in the aquatic environment and stabilization of the obtained solutions of the additive 0,72-1,36% of salts of succinic or citric acid.
The structure of the new substance is confirmed by elemental analysis data. Example 1. Di-(bromoacetate) zinc. To a suspension of 2.44 g (0.03 mol) of zinc oxide in 30 ml of distilled water is added at once to 8.34 g (0.06 mol) bromoxynil acid. The reaction mixture is stirred until almost complete dissolution of the precipitate (about 15 min) at room temperature, filtered slight mixture through filter paper on a Buchner funnel. Get 32 ml of 23.8% is astora salt bromoxynil acid and zinc. After freeze-drying an aliquot of the solution was obtained dry salt, and defined its elementary composition. C4H4Br2O4Zn. To stabilize the solution to it was added succinic acid in the amount of 0.3 was Calculated, %: C 14,06; N 1,17; Br 46,87; Zn 19,16. Found, %: C 13,95; N 1,12; Br 46,55; Zn 19,24. Example 2. Di-(trichloracetic) zinc. Obtained according to example 1 of the 2,44 g (0.03 mol) of zinc oxide, 9.81 g (0.06 mole) of trichloroacetic acid and 20 ml of distilled water. The concentration of the salts - 36,3%. C4Cl6O4Zn. To stabilize the solution was added 0.3 g of citric acid. Calculated, %: 12,30; Cl 54,56; Zn X 16.75. Found, %: C KZT 12.39; Cl 54,47; Zn 16,62. Example 3. Di-(CHLOROACETATE) zinc. To a suspension of zinc hydroxide was obtained from 4.1 g (0.03 mol) of zinc chloride and 2.4 g (0.06 mol) of sodium hydroxide, add a solution 5,67 g (0.06 mol) of Chloroacetic acid in 25 ml of distilled water. Stirred at room temperature until almost complete dissolution of the precipitate, is filtered through filter paper on a Buchner funnel and get 22,5% solution of salt of Chloroacetic acid and zinc. After drying the aliquot was obtained dry salt, and defined its elementary composition. C4H4Cl2O4Zn. The solution is stabilized by the addition of 0.3 g of succinic acid. Calculated, %: C 19,02; N 1,59; Cl 28,13; Zn 25,91. Found, %: C 19,89; N 1,63; Cl 28,01; Zn 26,03. p> Example 4. Di-(2-chloropropionate) zinc.Obtained according to example 3 of 4.1 g (0.03 mol) of zinc chloride, 2.4 g (0.06 mol) of the hydroxide nartia with the subsequent processing of zinc hydroxide with a solution of 6.5 (0.06 mol) of 2-chloropropionic acid in 20 ml of distilled water. The concentration of the salts is 28.5%. C6H8Cl2O4Zn. The solution is stabilized by the addition of 0.3 g of citric acid. Calculated, %: C 25,68; N 2,85; Cl 25,32; Zn 23,32. Found, %: C 25,75; N 2,71; Cl 25,42; Zn 23,27. Example 5. Di-(2-methyl-3-bromopropionate) zinc. Obtained according to example 1 of the 2,44 g (0.03 mol) of zinc oxide, 10 g (0.06 mol) of 2-methyl-3-bromopropionic acid and 25 ml of distilled water. The concentration of the salts is to 30.3%. C8H12Br2O4Zn. The stable solution of 0.3 g of succinic acid. Calculated, %: C 24,16; N 3,02; Br 40,26; Zn 16,46. Found, %: C 24,03; N 3,15; Br 40,37; Zn 16,38. Example 6. Di-(3-bromopropionate) zinc. To a suspension 3,76 g (0.03 mol) of zinc carbonate in 30 ml of distilled water is added at once with stirring 9,18 g (0.06 mol) of 3-bromopropionic acid. The reaction mixture is stirred until complete cessation of carbon dioxide emissions is filtered turbidity through filter paper on a Buchner funnel. Get 25,9% solution of salt 3 bromopropionic acid and zinc. After freeze-drying an aliquot of the solution was obtained dry salt and studied its elementary composition. C H8Br2O4Zn. The stable solution of 0.3 g of citric acid. Calculated, %: C 19,49; N 2,17; Br 43,31; Zn 17,71. Found, %: C 19,58; N To 2.29; Br 43,22; Zn 17,62. Example 7. Di-(2,3-dibromopropionate)zinc. Obtained according to example 6 of the 3,76 g (0.03 mol) of zinc carbonate, 13,92 g (0.06 mol) of 2,3-dibromopropionate acid and 25 ml of distilled water. The concentration of the salts - 36,9%. With6H6Br4Zn. The stable solution of 0.3 g of succinic acid. Calculated, %: C 13,65; N 1,14; Br 60,68; Zn 12,40. Found, %: C 13,53; N 1,19; They Accounted For 60,54 Br; Zn 12,51. Example 8. Di-(...-iodated) zinc. Obtained according to example 1 of the 2,44 g (0.03 mol) of zinc oxide, 12 g (0.06 mol)...-todokanai acid and 30 ml of distilled water. The concentration of the salts to 30.1%. C4H4J2O4Zn. The stable solution of 0.3 g of citric acid. Calculated, %: C 11,02; H 0,92; J 58,34; Zn 15,02. Found, %: C 10,91; N 1,01; J 58,01; Zn 15,14. Example 9. Di-(triptorelin) zinc. Obtained according to example 1 of the 2,44 g (0.03 mol), at 6.84 g (0.06 mol) triperoxonane acid and 15 ml of distilled water. The concentration of the salts of 33.8%. C4F6O4Zn... Calculated, %: 16,47; F 39,12; Zn Of 22.44. Found, %: C 16,56; F 39,24; Zn 22,32. Example 10. Di-(fluoroacetate) zinc. Obtained according to example 6 of the 3,76 (0.03 mol) of zinc carbonate, 4.68 g (0.06 mol) forexpros acid and 15 ml of distilled water. The concentration of the salts is 27.3%. C4 H4F2O4Zn... Calculated, %: C 21,88; N 1,82; F 17,32; Zn 29,81. Found, %: C 21,82; N 1,73; F 17,44; Zn 29,69. Example 11. Di-(dichloroacetate) zinc. Obtained according to example 1 of the 2,44 g (0.03 mol) of zinc oxide, 7,74 g (0.06 mol) dichloracetic acid and 20 ml of distilled water. The concentration of the salts-30,2%. C4H2Cl4O4Zn. Calculated, %: C 14,94; N 0,62; Cl 44,18; Zn 20,35. Found, %: C 14.83; N 0.57; Cl 44,27; Zn 20,00. Example 12. Treatment of 11 patients with a diagnosis of ectopia of the cervix (uterine), which saw a recurrent pseudo (age from 26 to 32 years). For processing ectopy used a 30% solution of zinc salt malodorous acid. Depending on the volume of the nidus number of applications of the drug was different. When ectopia not exceeding a diameter of 0.5-0.8 mm, processing was performed 1 time per 2 days. For large volumes of defeat applique was used 1 time double overlay, then daily or every other day, for a total of 3-4 applications. The drug was applied with a swab in the form of an application on the affected area. The immediate effect was manifested in the appearance of whitish-yellow fabric with a clear, white color ischemic roller around the affected area, 2-3 day fabric was gray-white, with 3 days was a decrease in the size of the scab and it is rejection. On the place of rejection, the mucous of the cervix acquired a reddish tint. Duration epithelialization ranged from 10 to 14 days, during which came the young regeneration epithelium cervical mucous. With extensive lesions of the cervix, requiring deep destruction of tissue, the duration of epithelialization was increased to 3-5 weeks. As a side effects at the time of processing was observed a slight burning sensation. At the control examination after 3-4 day after the last treatment in almost all cases, it was noted the rejection of the scab and the presence of reddish-purple color of the mucous of the cervix. At the control examination after 2 weeks, the mucous of the cervix becoming pink-red hue, i.e. close to the normal color of the mucous of the cervix. When colposcopically study indicated the emergence of metaplastic (young) epithelium over the entire surface, i.e. the process of epithelialization. Cytology revealed stratified squamous epithelium. The follow-up period for patients with ectopia ranged from 12 days to 2 months. During this period only one (9,1%) patient in the presence of a previously extensive eroded surface of the cervix and probably because of the depth of the lesion is not marked complete epithelialization of the mucous. Thus, the overall efficiency is ü use of a solution of zinc salts malodorous acid allows 90% of cases to achieve a positive result in the treatment of ectopy (background diseases of the cervix. Example 13. Treatment of 7 patients diagnosed with genital warts, papillomaviruses infection (HPV) (age from 20 to 68 years). For the treatment of patients with papillomas were used 30% solution of zinc salt malodorous acid, was carried out 3-4 applications daily, if a large papillomas to 6. Directly in the process, there was a decrease in the volume of education "seivane", i.e. dehydration, mummification with the formation of whitish-yellow plaque. Before each subsequent treatment was removal of dead tissue. After the gradual exclusion on the skin remained within 7-14 days dark-bluish-brown spots. Cytological examination after treatment revealed the presence of squamous epithelium with no evidence of pathology. Of the 7 patients with papillomas after 2 months was observed recurrence of the disease in 1 patient, who initially had a papilloma in diameter not less than 4, see Thus, the primary effect in the treatment of warts is 100%. As follows from the examples, the use of the drug zinc salts and haloalkaliphilic acid shows its high efficiency in the treatment of ectopic cervix and papillomatosis skin of the genitals. The advantages of the drug is its good tolerability, no complications, healing without scar formation and the changes, the ease of implementation, safety for patients and medical staff, as well as no particular restrictions on its behavior. Thus, the claimed chemical substance zinc salts and haloalkaliphilic acids of the aliphatic series may be used effectively as a treatment for benign tumors of the skin and visible mucous membranes of the skin. Zinc salts and haloalkaliphilic acids of the aliphatic series
where in the formula the halogen atom may be fluorine (F), chlorine (Cl), bromine (Br), or iodine (J).
|